about
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandThe maternal transcriptome of the crustacean Parhyale hawaiensis is inherited asymmetrically to invariant cell lineages of the ectoderm and mesodermAntagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanomaSystems biology.High-throughput RNA isolation technologies. New tools for high-resolution gene expression profiling in plant systems.Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients.Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis.Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages.PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.Sorafenib in melanoma.Melanoma immunotherapy: historical precedents, recent successes and future prospects.Curing advanced melanoma by 2025.Hedgehog signaling in basal cell carcinoma.Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets.Metastatic melanoma moves on: translational science in the era of personalized medicine.MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations.Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failureNew tools for the identification of developmentally regulated enhancer regions in embryonic and adult zebrafish.miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.Epigenetic impacts of ascorbate on human metastatic melanoma cells.Basal cell carcinomas in a tertiary referral centre: a systematic analysis.Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma.NGS-pipe: a flexible, easily extendable, and highly configurable framework for NGS analysis.Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?Noncutaneous Melanomas: A Single-Center Analysis.An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.Auxin responses in mutants of the Arabidopsis CONSTITUTIVE PHOTOMORPHOGENIC9 signalosome.Perturbing resistance: a network perspective.Melanoma's next top model, it is in the air.
P50
Q30491702-9A592DED-28B6-4B9E-B52F-2DBE8744E8DDQ34589782-BA2B7775-008B-4631-9969-80599691386BQ35023613-09559C54-D57B-4118-841E-5A93EAA43871Q35229597-2C0FD3DC-F6A5-48E7-B0E0-3868CCFE70E6Q35694609-B4199510-EB9E-49FB-8E39-AB22DEC7E2FBQ36163089-E868AFE5-A6ED-4997-856B-F0FFA28285AAQ36176934-BDD22C4D-FB87-4E45-BCC7-E1D44307707EQ36377576-1629291A-03EE-4C5D-8C64-882F113409A0Q36636018-34D8546B-5AB0-432D-A4D9-F4546E2BAA3BQ36698266-BA3BEFC4-F7AC-462C-BB1D-BD32BE1F56FAQ36957604-4580374B-F015-4DE2-AE58-207E0A56A783Q37555493-CC4C72CE-8DA2-4EB0-BAF3-EBBA9F0D658EQ37688982-B716BC6C-75AA-409E-9910-4FFEAFFF487DQ37990977-1A96BCCF-BFF8-448D-A366-CDE636C99C60Q38081911-2737A883-87C7-440A-B918-78D4B055B8D8Q38342364-E94A5EBA-1A88-4497-AC39-BECDCC18CC48Q38376188-AAD1CECA-8276-4446-824C-BF758B61BD06Q38689427-DEADE2D4-87A8-4E31-A936-536FA79DAE44Q38701329-6893D4A3-6CDE-4957-994B-D8A049A18522Q38891959-4CE3EE9D-635B-4B6D-9C97-B24AA9991BE2Q39120374-5F39D53A-AE2C-43D3-A685-8BBCBFC8D6C7Q39124064-4D8554E6-78F0-489F-979C-8BE6FB4D8597Q40282288-49A84657-6425-4964-A992-AF91EEA6E914Q41153220-34C38D44-0BBA-4D12-9985-8F10D6284270Q41198115-60FFC15B-ED92-48EC-8064-B363DCDE8A48Q41428871-C3CFAE68-EBB4-46D0-A685-DF2979FE64ABQ41818086-B0734B47-42EC-4FE5-B2C2-E05AF282E527Q42002131-925D9CD5-901A-4DE6-A8CF-58A9AF337F33Q42461410-0B0E1154-2744-41C6-9BE8-2F5162F4C9E6Q42471540-5134970B-F014-4013-914F-1A8DB4F91391Q42696635-BD3782B2-AFEC-439D-A8D9-58785732F582Q45071326-54B49D16-F312-49A6-BDB5-BC2611C2D191Q47225234-5C65205F-F71C-4D41-A9AB-9BFAEEB15B48Q48183075-40F2B316-DF57-4E66-97C7-D6BD3BBA586BQ48351638-AE0D6C21-DB4B-4E9E-86F3-9D48AB1B7CCDQ50763990-BA2E74E2-A3F1-45A7-BF6A-FAA897386BABQ51746622-9707D54E-53B6-4E35-B6F2-60EDC23BD71AQ51957599-24C51767-A899-4ABC-81AA-1A115F5D8FA4Q53813286-0E99B6FE-C466-4884-B7B0-6E4D7C3212F8Q53843053-600B9909-6942-43D7-8FC6-622AA157DAF3
P50
description
investigador
@es
researcher
@en
name
Mitchell P Levesque
@en
Mitchell P Levesque
@nl
type
label
Mitchell P Levesque
@en
Mitchell P Levesque
@nl
prefLabel
Mitchell P Levesque
@en
Mitchell P Levesque
@nl
P31
P496
0000-0001-5902-9420